Bleomycin Sulfate

製品コードS1214 別名:NSC125066

Bleomycin Sulfate化学構造

分子量(MW):1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

サイズ 価格(税別)  
JPY 28220.00
JPY 111220.00

質量管理及び製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
体外試験

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NGXSTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxcmQx6oDVMUCwNEDPxG1? NWL0c5lqOjRiaNMg NWm1bZd[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NGDGRWszPjB6OEexNS=>
POLK WT M2Pjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFzLkhihKnDueLCiUGuO:Kh|ryP M33Xe|I3ODNzNECw
POLK KO M4KyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHNI5iUUN3ME20MlA{6oDLwsJihKkyNjl{wrFOwG0> NUPhfZNFOjZyM{G0NFA>
POLK CD NE\XR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;DUXZMUUN3ME21MlU66oDLwsJihKkyNjBywrFOwG0> NHvqPGgzPjB|MUSwNC=>
RLE/Abca3 M3q1WWZ2dmO2aX;uJGF{e2G7 NYHmZZZ1OC52wrFOwG0> M3jwWVE1PMLiaB?= NI\BUIFqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg MoDlNlU4PjB3M{i=
PMCs M4D1bGZ2dmO2aX;uJGF{e2G7 MnzlNE4y6oDVMtMg{txoN22u NHvvdogzPMLiaB?= NX\USIlr[2G3c3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIIDyc5RmcW5ibHX2[Ywhd2ZiY3;scIFo\W5vSdMg NUG1[lEzOjV3OUW2OFI>
PMCs NULGXJFTTnWwY4Tpc44hSXO|YYm= NH7KV2YxNjMEoN88[{9udA>? NFfyd5UzPOLCk{eyxsBp MojabY5lfWOnczDpcoNz\WG|ZYOgbY4hfmmvZX70bY4h[W6mIN8xMXNOSSCycn;0[Ylv Ml;MNlU2QTV4NEK=
PMCs NEW5RW5HfW6ldHnvckBCe3OjeR?= MlH6NE4zyqEQvHevcYw> Ml\qO|IhcA>? NHLp[W9qdmS3Y3XzJIRm[3KnYYPld{BqdiCleYTvb4Vz[XSrbj24JIFv\CCHLXPh[IhmemmwIIDyc5RmcW5? MX2yOVU6PTZ2Mh?=
PMCs M3fCPWZ2dmO2aX;uJGF{e2G7 NUTVXplmOC5{wrFOwIcwdWx? MYexNk8zPC92ODDo NUjmWIt4cW6lcnXhd4V{KGOnbHygcYloemG2aX;u NEX6fmkzPTV7NU[0Ni=>
IMR-32 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\XephlPy534pkSNVIxKML3Zz;tcC=> NWD0WlE3OTMkiKK0PEBp NYj2UIx6UUN3ME22NEDDvWdxbXygZZQhfGinIHXu[EBw\iB{NDDodpMhd2ZiaX7jeYJifGmxbh?= NH:wVGIzPTV|NkO0OS=>
HT1080 NVHGe|k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xJO69VQ>? NWrL[YtROjRiaNMg M2LaVYxm[WS|IITvJIEhTzJxTTDk[YxigQ>? MYGyOVUyQDl4MR?=
HT1080 M1faS2Z2dmO2aX;uJGF{e2G7 M3;kSVEh|ryP NV\VfnBNOjRiaNMg MUfpcoR2[2W|IHGgdI91\W62IHfsc4JidCCGTlGg[IFu[WenIILld5BwdnOn NUDTWWQ4OjV3MUi5OlE>
HDFn M3XmdGN6fG:2b4jpZ4l1gSCDc4PhfS=> Mk\lO|IhcA>? MUjJR|UxRTlwM{GlxsA> NE\NTWQzPTJ5Nke5Ni=>
THP-1 M3e5[2N6fG:2b4jpZ4l1gSCDc4PhfS=> NYLXSY9IPzJiaB?= NIXJdWlKSzVyPUSuO|cm MlLRNlUzPzZ5OUK=
HT-29 M{GwcGN6fG:2b4jpZ4l1gSCDc4PhfS=> MmKzO|IhcA>? NU\E[nd[UUN3ME2xNU41QSV? MlfENlUzPzZ5OUK=
HCT116  MUXDfZRwfG:6aXPpeJkhSXO|YYm= M4jkTFczKGh? MUDJR|UxRTFzLkO0KS=> MUKyOVI4Pjd7Mh?=
A431 NUnKcWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi1NE0zODBiSWW= MlrtOFjjiImq MUPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MnvzNlUyODF{OUm=
T24 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2SmpRPTBvMkCwJGlW M2\Tb|Q56oDLaB?= NHrkSmJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXPCT214OjVzMEGyPVk>
AY-27  Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC1NE0zODBiSWW= MVO0PQKBkWh? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NIPWOnczPTFyMUK5PS=>
A549 M37WSGZ2dmO2aX;uJGF{e2G7 MWSxJOK2\y:vTNMg NWS1[XJlOC12ODDo NXXybYxKcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? M36zSVI1QTZ|NkO1
MLE12 NYflVVlxTnWwY4Tpc44hSXO|YYm= MnLvNUDDvWdxbV|CpC=> NHLFUIQxNTR6IHi= Mn;4bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBQWE8EoH3SUmE> NGDxbXozPDl4M{[zOS=>
Jurkat NEnGd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqyNQKBkc7:bR?= NVi1UnNrOjUkgJnoxsA> M3y0[4FzemW|dIOgeIhmKGOnbHygZ5lkdGViYYSgeIhmKEd{IIDoZZNm M13GRlI1QTF4OEmz
HeLa  M4i2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\6[WlEPTB;MUCuNuKh|ryP MVyyOFc{OjN7Nx?=
C18-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMVExOCEQvF2= MX3pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MUSyOFU4OTl6Mh?=
BMG-1  Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq3eo81OC96MNMg{txoN21? MWqzxsBp NVv6SpZFcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Mlv5NlM6ODZ5Mk[=
A459 Mn\3RZBweHSxc3nzJGF{e2G7 NUfV[HpmOTBibWW= Ml34OFghcA>? MY\pcoR2[2W|IHHwc5B1d3Orcx?= M3XoOlI{QTB{N{[2
MOCK MYPBdI9xfG:|aYOgRZN{[Xl? NHPabZQyOCCvVR?= MnTYOFghcA>? NFHFZWRqdmS3Y3XzJIFxd3C2b4Ppdy=> MoLzNlM6ODJ5Nk[=
MMP1 MYnBdI9xfG:|aYOgRZN{[Xl? NGX6ZmQyOCCvVR?= MXu0PEBp NHnQO2tqdmS3Y3XzJIFxd3C2b4Ppdy=> NWf3[FJIOjN7MEK3OlY>
A549 M1TTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHQZpAzODBizszN MVeyOEBpyqB? NFT4[|Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MUKyN|gxPTd7Mx?=
HCT-116 M2Dj[2Fxd3C2b4Ppd{BCe3OjeR?= MlTJN{84NjVxMUWg{txoN22u NWTYNZBYPDhiaB?= M{naXpJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> NVHnS4JEOjN5MEi2Olg>
HeLa NFLYNlNCeG:ydH;zbZMhSXO|YYm= NX62XWtOOy95LkWvNVUh|rypL33s MXG0PEBp M1vQWZJm\HWlZYOgeIhmKGyndnXsJI9nKEKOSDDheEBpcWeqIHPvcoNmdnS{YYTpc44> Mmj1NlM4ODh4Nki=
HCT116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWCwMVExOCEQvHevcYw> MnzLOFghcA>? MkPBbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NGruTlUzOzVzOEKwNS=>
NCM460 M3W5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\IcFAuOTByIN88[{9udA>? MUS0PEBp M4\OPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3\5OVI{PTF6MkCx
NT2  MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrWeHYzPCCqwrC= MWHMSFUxRTRyMPMAjeK2\y:vbB?= NUfRcYx2OjN|OE[0NlA>
NT2  M4r1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK0PEBp MkjyUGQ2OD1zMECgxtVoN22u M1;zOFI{Ozh4NEKw
NT2  M364d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX3e|I4OiCq M4XWcmxFPTB;MkFihKnDvWdxbXy= NHvudJozOzN6NkSyNC=>
NT2  MnvQRZBweHSxc3nzJGF{e2G7 NYfYXodnPDBy4pEJxtVoN22u M3S0UlI1KGkEoB?= NFXqPZBqdmS3Y3XzJJNq\26rZnnjZY51KGmwY4LlZZNmeyCrbjDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? NX7VTFhnOjN|OE[0NlA>
NTera-2 NIHzTlFHfW6ldHnvckBCe3OjeR?= MU[xNlAh|rypL33s M3foc|czKGh? M2jBb5Nq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz M4\tN|IzQDJ3M{W1
NCCIT NWrrSollTnWwY4Tpc44hSXO|YYm= M{T1e|EzOCEQvHevcYw> NFfZe4Y4OiCq Mlnvd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= MUCyNlgzPTN3NR?=
NTera-2 NYLzRnJ[TnWwY4Tpc44hSXO|YYm= M1zuTlEzOCEQvHevcYw> M{DST|czKGh? NV\MPJlve2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ M{nHS|IzQDJ3M{W1
NCCIT MUHGeY5kfGmxbjDBd5NigQ>? NH[0fmIyOjBizsznM41t MWi3NkBp M{f1Z5Nq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> NUTiPXJrOjJ6MkWzOVU>
NCCIT NGHPfW5HfW6ldHnvckBCe3OjeR?= MWOxNlAh|rypL33s NXPQcWQ6PzJiaB?= M3S3SZNq\26rZnnjZY51dHliZHXjdoVie2W|IFfTTEBt\X[nbIO= MoPLNlI5OjV|NUW=
NTera-2 MlnFSpVv[3Srb36gRZN{[Xl? M{f0ZVEzOCEQvHevcYw> MmLQO|IhcA>? M4DWRpNq\26rZnnjZY51dHliaX7jdoVie2W|IGDyc5RmcW5iY3HyZo9vgWxibHX2[Yx{ NFvRTG4zOjh{NUO1OS=>
NCCIT NFnacYxHfW6ldHnvckBCe3OjeR?= NUL0[3U6OTJyIN88[{9udA>? MWG3NkBp MWrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> NH;2OVIzOjh{NUO1OS=>
NTera-2 NGP3NpdHfW6ldHnvckBCe3OjeR?= NVHrWZBXOTJyIN88[{9udA>? NXK5e41[PzJiaB?= NX:2WnBCe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> MVyyNlgzPTN3NR?=
NCCIT NFHLfJNHfW6ldHnvckBCe3OjeR?= NFnwSVcyOjBizsznM41t NHHK[JA4OiCq NV[4NZB2e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgUHBQKGyndnXsdy=> NXTu[mVtOjJ6MkWzOVU>
MDA-MB-468 M3\RfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWw5qCUOjBywrFOwIcwdUx? NYexNXN2OjRiaB?= NXLwTWlXcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUiyNlgyQTF7Nh?=
231-H2N MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P0NlDjiJN{MEFCpO69\y:vTB?= MXWyOEBp NYTnSYRKcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Ml;rNlI5OTlzOU[=
A549  MUPGeY5kfGmxbjDBd5NigQ>? MoD3NlAxNzRyMDFOwG0> M1H3UpJme3WudIOgbY4h[SCmb4PlMZJme3CxboPpeoUhcW6lcnXhd4UhcW5iUl;T Mnr1NlI4PzN4OUe=
A549  M1;2eGZ2dmO2aX;uJGF{e2G7 M4PzclAuPDByIN88US=> NGSx[3QzNTR6IHi= NYTmNYZb[2G3c3XzJI1wemVibYTEUmEhfGijbjDuSG5CKGSjbXHn[S=> NUfjTI9EOjJ5N{O2PVc>
A549  NXm1THVRTnWwY4Tpc44hSXO|YYm= NHjMW44yODBizszNxsA> NETU[pMx6oDVNEigbC=> MWPjZZV{\XNiY3HzdIF{\S1|IHHjeIl3[XSrb36= MWKyNlc4OzZ7Nx?=
A549  M4H1PWZ2dmO2aX;uJGF{e2G7 Ml:2NVAxKM7:TdMg NF;VXlAx6oDVNEigbC=> NVu4WnNQ[2G3c3XzJHBMTDFiY3zlZZZi\2V? NFrTZXYzOjd5M{[5Oy=>
A549  NEXmbGtHfW6ldHnvckBCe3OjeR?= NGqwdlIyODBizszNxsA> M37pN|DjiJN2ODDo MojGZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? MYKyNlc4OzZ7Nx?=
A549  NXuzSlVuTnWwY4Tpc44hSXO|YYm= MoXqNVAxKM7:TdMg MnzpNQKBmzR6IHi= NF3m[nVl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ M4H0eFIzPzd|Nkm3
MCF-7/Her-18  NH;OPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrBNmFjOC52Mj2xO|AxKM7:Zz;tUC=> NHXPfHAzPCCq MmfubY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1uxPVIzPjJzNEC0
MCF-7 NHTQRoFRTFRxUFPJJHRz\WG2bXXueC=> MlK4NE4zPSEQvHevcYwv NYLyUpA2OS12IHi= MYLzbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 MW[yNlU6OTJ6NB?=
MDA-MB-231 Mn;QVGRVN1CFSTDUdoVifG2nboS= NUDzRnpWOC5{NTFOwIcwdWxw M4D6SlEuPCCq NIe5WlF{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NFvON4MzOjV7MUK4OC=>
MDA-MB-235  MWXQSHQwWEOLIGTy[YF1dWWwdB?= Mom4NE4zPSEQvHevcYwv Ml\2NU01KGh? NGDHdJN{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 M3zMSlIzPTlzMki0
MCF-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTJVnIxNTJizsznM41tNg>? Mn24NlQwPDhiaB?= NYDRNIplTUN3ME2xMlIh|rypL33M M{nDSFIzPTlzMki0
NCCIT  M2\OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITzd|YzOOLCk{G0NOKh|rypL33s NV7pN|VvPzJiaB?= MU\MSFUxRTF{MNMg{txoN22uwrC= MYSyNlU3OjF4MB?=
NCCIT  MYjGeY5kfGmxbjDBd5NigQ>? MoezO|IhcA>? NF7k[IR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOgZYN1cX[rdIpCpC=> M2O3d|IzPTZ{MU[w
NCCIT  MUXGeY5kfGmxbjDBd5NigQ>? MkDnO|IhcA>? NEDoe2x{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> NXLqNVZNOjJ3NkKxOlA>
NCCIT  M2fwdmZ2dmO2aX;uJGF{e2G7 MlroO|IhcA>? M3r4SpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg M3LZRVIzPTZ{MU[w
NCCIT  MX3GeY5kfGmxbjDBd5NigQ>? MYG3NkBp NVzGUVNte2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs NGTXeoMzOjV4MkG2NC=>
NCCIT  NWfWPFZETnWwY4Tpc44hSXO|YYm= NU\aV3o3PzJiaB?= MnPld4lodmmoaXPhcpRtgSCmZXPy[YF{\XNidHjlJGJkdC1{IHPvcpRmdnR? NIPhPWkzOjV4MkG2NC=>
NCCIT  M2D6cGZ2dmO2aX;uJGF{e2G7 M1nFXFczKGh? NELPfnN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhS3m2LXOgcIV3\Wx? NWDx[opvOjJ3NkKxOlA>
HeLa M3LpXmZ2dmO2aX;uJGF{e2G7 MXizNE84OCEQvHevcYw> NVzhdoVMOjUEoHi= NF2xfnVqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCyNURvwKxCXE1ucEKxxsBidmUEoFfBSGQ1PQ>? NH3WZpEzOjR6N{mzOy=>
MCF-7  MkLnSpVv[3Srb36gRZN{[Xl? MUmzNE84OCEQvHevcYw> MYeyOOKhcA>? NV21V2JwcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLicEWz89yNSVSPLICyNeKh[W6mwrDHRWRFPDV? MYqyNlQ5Pzl|Nx?=
HeLa NInVXZREgXSxdH;4bYNqfHliQYPzZZk> M3WyelMxNzdyIN88[{9udA>? NFjwcngzPMLiaB?= NXXlR24xcW6mdXPld{BpcWeqbImgd4lodmmoaXPhcpQhdGW4ZXzzJI9nKG[{YXft[Y51\WRiRF7BJJJmdGWjc3WgbY51dyC2aHWgZ5l1d3CuYYPt NXT6c|BQOjJ2OEe5N|c>
MCF-7  NYmzZWxkS3m2b4TvfIlkcXS7IFHzd4F6 NUH5WG9JOzBxN{Cg{txoN22u NGmzcIkzPMLiaB?= Ml\tbY5lfWOnczDobYdpdHlic3nncolncWOjboSgcIV3\Wy|IH;mJIZz[WevZX70[YQhTE6DIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOv MV:yNlQ5Pzl|Nx?=
NT2 M1SyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWdIc{OTByLU[wNOKh|rypL33s Mn\TNlQhcA>? NYTLdlRNUUN3ME20NFAhyrWpL33s MWiyNlQ3QTl3Mh?=
NT2 NY\6U3N{TnWwY4Tpc44hSXO|YYm= MYm0NFDDqM7:Zz;tcC=> M13wclI1KGh? NF3EfVR{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUOsPEw6KGGldHn2bZR6yqB? M3nCWFIzPDZ7OUWy
NT2 NETIbWlHfW6ldHnvckBCe3OjeR?= MoPxOFAxyqEQvHevcYw> MUOyOEBp Mki2d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiQlHYJIxmfmWu MnP6NlI1Pjl7NUK=
NT2 NYq4VIVXTnWwY4Tpc44hSXO|YYm= M2DkW|QxOMLizsznM41t NWTIOHdHOjRiaB?= MWjzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCEY3ytNkBt\X[nbB?= MW[yNlQ3QTl3Mh?=
CHO MVvGeY5kfGmxbjDBd5NigQ>? NYnmNYxYOi53wrFOwIcwdWx? MlXJNVghcC94IHS= NFPTS4FqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= MkPINlIzOzBzOUW=
Jurkat MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK0VGMxNTFyMNMg{txoN22u MWSyOEBp MVvhdpJme3S|IITo[UBk\WyuIHP5Z4xmKGG2IITo[UBIOiCyaHHz[S=> M13IOlIzOjJ|M{Oy
Jurkat M2jBbmZ2dmO2aX;uJGF{e2G7 M{C1[|MxyqEQvHevcYw> NIXodmEzPCCq NInEem5qdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIHP5Z4xqdnNiREOsJGEh[W6mIFKx MVqyNlIzOzN|Mh?=
Jurkat M1XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[xW|UxNTFyMNMg{txoN22u MnzQNlQhcA>? NIfKNJhqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDhckBKSzVyII\hcJVmKG:oIEGwNO69\y:vTB?= MUWyNlIzOzN|Mh?=
Jurkat Mln1SpVv[3Srb36gRZN{[Xl? NF\rOG4{OMLizsznM41t NHuxNXAzPCCq M2jldYlv[3KnYYPld{B1cGViZX\m[YN1KG:oIID5Z45q\GmxbnWgc44heGixc4Doc5J6dGG2aX;uJIxmfmWuczDv[kBpcXO2b37lJGgzSS6[ MoLlNlIzOjN|M{K=
U2OS EGFPnls MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fobVAuOsLizsznM41t M1zlPFI1KGh? MlfGbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NEXD[5UzOThzMUCwOy=>
U2OS KuEnls M{DhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tNE0zyqEQvHevcYw> NXT6NXhkOjRiaB?= NIP2RW1qdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXTXcmJUOjF6MUGwNFc>
MCF-7 M3f0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr3eVIxNTRyMDFOwG0> NVrtZoFOPzJiaB?= NHHuOHZNSzVyPUG1NU45yqEQvF2= NVLsNpBWOjF5MEOyPVE>
MCF-7/Adr  NFnHVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsNE01ODBizszN M13mNVczKGh? MXfMR|UxRTV6LkZCpO69VcLi NHfG[ZUzOTdyM{K5NS=>
WI-38 M3XTbWZ2dmO2aX;uJGF{e2G7 MWSwM|QxNzhy4pEJ{txoN22uwrC= NUf4ZlYyOyCq NIDNd3JqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh Mmj5NlE2QTl4MUK=
hBMSC NHi2NnBHfW6ldHnvckBCe3OjeR?= MWWwM|QxNzhy4pEJ{txoN22uwrC= NYPkXnR3OyCq MoHubY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> MnvINlE2QTl4MUK=
NCI-H23 NYXUNoFUTnWwY4Tpc44hSXO|YYm= MlPTNE81OC96MPMAje69\y:vbNMg MYKzJIg> NYjQVWR6cW6mdXPld{BiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JIlv[3KnYYPlJIlvKHSqZTDNUkBnemWzdXXuZ5nDqA>? MYCyNVU6QTZzMh?=
A-549 MUPGeY5kfGmxbjDBd5NigQ>? NHqwb|MxNzRyL{iw5qCK|rypL33sxsA> MUizJIg> M1\Pfolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MlLNNlE2QTl4MUK=
PBL  MX7GeY5kfGmxbjDBd5NigQ>? MVewM|QxNzhy4pEJ{txoN22uwrC= NVfpeGh3OyCq M2PSSolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NYrQeoZYOjF3OUm2NVI>
pol β −/− Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle5NE4zPS1{MEFCpO69\y:vbB?= NYLIUYNROjUEoHi= NVz2fWZt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NIn2U3ozOTJ3MUm0OC=>
pol β +/+ NGXLOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWwMlI2NTJyMNMg{txoN22u MX[yOOKhcA>? NHPyW4pl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? Ml3qNlEzPTF7NES=
pol β −/− NUDQWGp5TnWwY4Tpc44hSXO|YYm= MXWwMVIvPSEQvHevcYw> MW[yJIg> NWrReWR3[2G3c3XzJGRPSSCmYX3h[4U> MnGzNlEzPTF7NES=
pol β +/+ NEGxWpBHfW6ldHnvckBCe3OjeR?= MV[wMVIvPSEQvHevcYw> M2LUb|IhcA>? MojCZ4F2e2W|IFTORUBl[W2jZ3W= NVXoXXZHOjF{NUG5OFQ>
pol β −/− NF7CW|JHfW6ldHnvckBCe3OjeR?= M1L0ZVAuPSEQvHevcYw> MVO0PEBp NGfVZ5pk[XW|ZYOgcYlkem:wdXPs[ZV{KGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NFHl[3czOTJ3MUm0OC=>
pol β +/+ NIXITnlHfW6ldHnvckBCe3OjeR?= NHfITlExNTVizsznM41t NVy0cXd[PDhiaB?= NWq0dWpj[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M{K2ZlIyOjVzOUS0
TK6  NUj2cohOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1VHczPS1zNUCg{txoN22u NFvHVlE6PiCq MnvwbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXvsTGxLOjFyOEG0PFc>
TK6  sLUC+Apn1 NGezc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTZUHM2OjVvMUWwJO69\y:vbB?= NXTQeIxrQTZiaB?= MmHPbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYr0T21wOjFyOEG0PFc>
TK6 sAPE1+Apn1 NVvxPIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j0clI2NTF3MDFOwIcwdWx? NIe3Xnk6PiCq M2rYb5Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEBoem:5dHig[I9{\SCmZYDlcoRmdnSueR?= MnfINlExQDF2OEe=
HCT116 NGPDfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;lW|I2NTF3MDFOwIcwdWx? M4fLXlk3KGh? M{TZeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M4DGbFIyODhzNEi3
HCT116 sLUC+Apn1 NGLNdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLhNlUuOTVyIN88[{9udA>? NX\1O3F2QTZiaB?= NV\PXGpqcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MYGyNVA5OTR6Nx?=
HCT116 sAPE1+Apn1 NYjLfo5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPuNVEzPS1zNUCg{txoN22u NV7oS5RuQTZiaB?= NEHaSGl{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= Mk\NNlExQDF2OEe=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

お薦めの試験操作(参考用のみ)

細胞試験:

[4]

+ 展開
  • 細胞株: ADIPO-P2 cells
  • 濃度: 2.5 μg/mL
  • 反応時間: 30 minutes
  • 実験の流れ:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: CD-1 mice
  • 製剤: Saline
  • 投薬量: 5 mg/kg, 2 ml/kg
  • 投与方法: Administered via i.t.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (66.11 mM) warming
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
Saline
混合させたのち直ちに使用することを推奨します。
30 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 1512.62
化学式

C55H85N17O25S4

CAS No. 9041-93-4
保管
別名 NSC125066

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • 回答:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Bleomycin Sulfateを買う | Bleomycin Sulfate ic50 | Bleomycin Sulfate供給者 | Bleomycin Sulfateを購入する | Bleomycin Sulfate費用 | Bleomycin Sulfate生産者 | オーダーBleomycin Sulfate | Bleomycin Sulfate化学構造 | Bleomycin Sulfate分子量 | Bleomycin Sulfate代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID